Celldex's Phase 1b Study on Barzolvolimab for Prurigo Nodularis to be Presented at 12th World Congress on Itch 2023 in Miami
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the Phase 1b study of barzolvolimab in patients with prurigo nodularis has been accepted as an oral presentation at the 12th World Congress on Itch in Miami. The study is a multi-center, randomized, double-blind, placebo-controlled trial designed to study barzolvolimab in patients with prurigo nodularis, a chronic skin disease.

September 26, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celldex's Phase 1b study on barzolvolimab has been accepted for presentation at a major conference, which could potentially increase visibility and interest in the company's work.
The acceptance of Celldex's study for presentation at a major conference increases the visibility of the company's work and could potentially attract more interest from investors and partners. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100